SEOUL, Oct. 28 (Yonhap) -- Yuhan Corp., a South Korean biopharmaceutical company, said Monday its third-quarter net profit ...

Yuhan-Kimberly, a joint venture between Korea’s Yuhan Corp. and America’s Kimberly Clark, has been chosen as one of the ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...

J INTS BIO will oversee the entire project, managing clinical trials to validate AI-based predictions and develop clinically ...

Yuhan Li is Associate Director of Learning Design in the Center for Digital Innovation in Learning at Boston College. With nearly 8 years of experience supporting faculty teaching in higher education, ...